DexCom, Inc. (NASDAQ:DXCM) Downgraded by BidaskClub

BidaskClub downgraded shares of DexCom, Inc. (NASDAQ:DXCM) from a hold rating to a sell rating in a research note issued to investors on Monday, July 24th.

DXCM has been the subject of several other research reports. Jefferies Group LLC lowered their target price on shares of DexCom to $91.00 and set a buy rating for the company in a research note on Tuesday, May 9th. Canaccord Genuity reiterated a buy rating and set a $90.00 target price on shares of DexCom in a research note on Wednesday, June 7th. Zacks Investment Research upgraded shares of DexCom from a sell rating to a hold rating in a research note on Tuesday, July 18th. Cowen and Company reiterated a buy rating and set a $90.00 target price on shares of DexCom in a research note on Friday, July 14th. Finally, Royal Bank Of Canada restated an outperform rating and set a $87.00 price target on shares of DexCom in a research report on Tuesday, April 4th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and fifteen have given a buy rating to the company’s stock. DexCom presently has a consensus rating of Buy and an average target price of $87.00.

DexCom (NASDAQ:DXCM) opened at 69.60 on Monday. DexCom has a 52-week low of $57.68 and a 52-week high of $96.38. The stock’s market capitalization is $6.02 billion. The company has a 50 day moving average of $71.12 and a 200-day moving average of $75.17.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.07. The business had revenue of $170.60 million during the quarter, compared to analyst estimates of $166.54 million. DexCom had a negative net margin of 10.27% and a negative return on equity of 27.90%. The business’s revenue was up 24.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.24) earnings per share. Equities research analysts anticipate that DexCom will post ($0.77) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Transcript Daily and is the property of of Transcript Daily. If you are reading this piece of content on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://transcriptdaily.com/2017/08/13/dexcom-inc-nasdaqdxcm-rating-lowered-to-sell-at-bidaskclub-updated-updated.html.

In related news, EVP Steven Robert Pacelli sold 1,450 shares of the stock in a transaction that occurred on Friday, June 23rd. The stock was sold at an average price of $78.19, for a total value of $113,375.50. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Kevin R. Sayer sold 8,649 shares of the stock in a transaction that occurred on Wednesday, May 17th. The stock was sold at an average price of $68.39, for a total value of $591,505.11. Following the completion of the transaction, the chief executive officer now owns 347,329 shares in the company, valued at approximately $23,753,830.31. The disclosure for this sale can be found here. Insiders have sold 36,375 shares of company stock valued at $2,549,351 over the last ninety days. Insiders own 1.70% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in the company. Independent Portfolio Consultants Inc. boosted its stake in shares of DexCom by 0.4% in the second quarter. Independent Portfolio Consultants Inc. now owns 2,499 shares of the medical device company’s stock worth $183,000 after buying an additional 9 shares during the last quarter. Bbva Compass Bancshares Inc. boosted its stake in shares of DexCom by 1.9% in the second quarter. Bbva Compass Bancshares Inc. now owns 3,670 shares of the medical device company’s stock worth $268,000 after buying an additional 69 shares during the last quarter. Mn Services Vermogensbeheer B.V. boosted its stake in shares of DexCom by 3.8% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 2,254 shares of the medical device company’s stock worth $179,000 after buying an additional 83 shares during the last quarter. Public Employees Retirement Association of Colorado boosted its stake in shares of DexCom by 0.4% in the second quarter. Public Employees Retirement Association of Colorado now owns 18,613 shares of the medical device company’s stock worth $1,362,000 after buying an additional 83 shares during the last quarter. Finally, King Luther Capital Management Corp boosted its stake in shares of DexCom by 0.7% in the first quarter. King Luther Capital Management Corp now owns 12,105 shares of the medical device company’s stock worth $1,026,000 after buying an additional 90 shares during the last quarter.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply